Simcere Subsidiary, Accused Of Illicitly Producing Substandard Rabies Vaccine, Faces Fine Of RMB 25 Million In China
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Simcere Pharmaceutical Group, maker of innovative drugs and branded generics, has announced disappointing first quarter results, hindered by ongoing difficulties at vaccine maker Jiangsu Yanshen Biological Technology and a sales decline for some traditional best sellers